ZBH Overview

Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is100.47 USD with a low forecast of 88.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zimmer Biomet Holdings, Inc revenue for the last quarter amounts to 2.09B USD, increased 9.30

Zimmer Biomet Holdings, Inc. EPS for the last quarter amounts to 1.22 USD, increased 34.07

Zimmer Biomet Holdings, Inc (ZBH) has 17000 emplpoyees as of May 31 2026.

Today ZBH has the market capitalization of 15.93B USD.